These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 6858823)
41. The use of procaine amide and lidocaine in the treatment of cardiac arrhythmias. Bigger JT; Heissenbuttel RH Prog Cardiovasc Dis; 1969 May; 11(6):515-34. PubMed ID: 4892943 [No Abstract] [Full Text] [Related]
42. Agranulocytosis following procainamide administration. Wang RI; Schuller G Am Heart J; 1969 Aug; 78(2):282-4. PubMed ID: 5797276 [No Abstract] [Full Text] [Related]
43. [Procainamide induced agranulocytosis]. Rollag A Tidsskr Nor Laegeforen; 1982 Jan; 102(2):96-7. PubMed ID: 7101253 [No Abstract] [Full Text] [Related]
44. Plasma concentration of procainamide and prevalence of exertional arrhythmias. Gey GO; Levy RH; Fisher L; Pettet G; Bruce RA Ann Intern Med; 1974 Jun; 80(6):718-22. PubMed ID: 4832159 [No Abstract] [Full Text] [Related]
45. Pure red cell aplasia associated with administration of sustained-release procainamide. Giannone L; Kugler JW; Krantz SB Arch Intern Med; 1987 Jun; 147(6):1179-80. PubMed ID: 3036033 [TBL] [Abstract][Full Text] [Related]
46. Agranulocytosis, procainamide, and phenytoin. Fleet S Ann Intern Med; 1984 Apr; 100(4):616-7. PubMed ID: 6703561 [No Abstract] [Full Text] [Related]
47. Use of plasma levels in evaluation of procainamide dosage. Shaw TR; Kumana CR; Royds RB; Padgham CM; Hamer J Br Heart J; 1974 Mar; 36(3):265-70. PubMed ID: 4132893 [No Abstract] [Full Text] [Related]
48. Thrombocytopenia following sustained-release procainamide. Meisner DJ; Carlson RJ; Gottlieb AJ Arch Intern Med; 1985 Apr; 145(4):700-2. PubMed ID: 2580499 [TBL] [Abstract][Full Text] [Related]
53. Septic complications of procainamide-induced agranulocytosis: report of two cases. Freed JS; Reiner MA Mt Sinai J Med; 1988 Mar; 55(2):194-7. PubMed ID: 3290673 [No Abstract] [Full Text] [Related]
54. Activity of Procanbid, procainamide twice-daily formulation, to suppress ventricular premature depolarizations. The Study Group Investigators. Kerin NZ; Meengs WL; Timmis GC; Salerno D; Haber HE; Singer RM Cardiovasc Drugs Ther; 1997 Apr; 11(2):169-75. PubMed ID: 9140693 [TBL] [Abstract][Full Text] [Related]
55. Reversible procainamide-induced agranulocytosis twice in one patient. Konttinen YP; Tuominen L Lancet; 1971 Oct; 2(7730):925. PubMed ID: 4106683 [No Abstract] [Full Text] [Related]
56. Pharmacokinetic of procainamide in man. Koch-Weser J Ann N Y Acad Sci; 1971 Jul; 179():370-82. PubMed ID: 5285382 [No Abstract] [Full Text] [Related]
57. Procainamide-induced pseudo-obstruction in a diabetic patient. Peterson AM; Conrad SD; Bell JM DICP; 1991 Dec; 25(12):1334-5. PubMed ID: 1815428 [TBL] [Abstract][Full Text] [Related]